This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Primary pulmonary arterial hypertension (idiopathic/heritable pulmonary arterial hypertension)Primary Pulmonary Arterial Hypertension (Idiopathic/Heritable PAH)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I27.0 | Special Copayment Reduction: V202 | Coverage period: 5 years
B. SynonymsIdiopathic pulmonary arterial hypertension (IPAH), heritable pulmonary arterial hypertension (HPAH), primary pulmonary hypertension (PPH), group 1 pulmonary arterial hypertension (WHO Group 1 PAH)
C. Adult onsetLikelihood of first onset in adulthood: high — female (F:M≈2:1), mean age at diagnosis 35–50 years; pediatric onset also exists, but adults are the main patient group
1. History1891 first described by Romberg; 1951 Dresdale named it "primary pulmonary hypertension"; 2000s BMPR2 gene identified; arrival of the era of multidrug combination therapy
2. CausesBMPR2 variants (~75% of heritable PAH), abnormal TGF-β signaling pathway; endothelial dysfunction, vascular smooth muscle proliferation, vascular remodeling
3. GeneticsBMPR2 (autosomal dominant, penetrance ~20% males·42% females); ACVRL1, ENG, SMAD9, CAV1, KCNK3, ATP13A3, SOX17, etc.
4. EpidemiologyPrevalence about 15–60/1,000,000; annual incidence about 2–7/1,000,000; female predominance (F:M≈2–3:1); mean age at diagnosis 35–50 years
5. PathophysiologyBMPR2 loss of function → impaired inhibition of endothelial·smooth muscle cell proliferation → vascular remodeling → increased PVR → increased right ventricular afterload → right ventricular failure
6. SymptomsExertional dyspnea (early), fatigue, syncope, chest pain; at end stage, dyspnea at rest·symptoms of right heart failure
7. SignsAccentuated P2, palpable right ventricular impulse, elevated jugular venous pressure, lower-extremity edema, hepatomegaly; signs of right ventricular failure
8. ScreeningEchocardiographic screening in families with BMPR2 variants; screening for pulmonary hypertension in patients with connective tissue disease·HIV·congenital heart disease
9. DiagnosisRight heart catheterization (RHC): mPAP≥25 mmHg, PAWP≤15 mmHg, PVR>3 WU are the diagnostic criteria; exclusion of other causes essential
10. TreatmentRisk-based initial combination: ERA+PDE5i; add intravenous prostacyclin for high risk; sGC stimulator (riociguat); sotatercept (new)
11. PrognosisMean survival 2.8 years without treatment; 5-year survival 60–70% with modern combination therapy; poor prognosis in BMPR2 variant carriers
12. PreventionFollow-up screening of BMPR2 carriers; avoid oral contraceptives·appetite suppressants; management at a specialized center during pregnancy; early diagnosis to start upfront combination therapy
References10 key references including PMID/DOI

1. Historical background

The history of Pulmonary Arterial Hypertension (PAH) dates back to 1891, when the German physician Ernst von Romberg first described "sclerosis of the pulmonary vessels". Later, in 1951, the American cardiologist Micheal Dresdale named the syndrome of right ventricular failure due to increased pulmonary vascular resistance of unclear cause "primary pulmonary hypertension (PPH)", the first naming corresponding to what is now idiopathic pulmonary arterial hypertension (IPAH).

In the 1960s–1970s, a surge of PAH among people who had taken an appetite suppressant (aminorex fumarate) in Europe (mainly Switzerland and Austria) revealed that external factors can induce PAH. Together with later cases of PAH caused by fenfluramine-class appetite suppressants, this event became an important lesson about drug-induced PAH. In 2000, two research teams independently identified germline mutations in the BMPR2 (bone morphogenetic protein receptor type 2) gene as the cause of familial PAH, and BMPR2 was subsequently established as the main causative gene of heritable PAH.

In terms of treatment, a new era of PAH treatment began in 1995 when intravenous epoprostenol received FDA approval. Subsequently, endothelin receptor antagonists (bosentan, ambrisentan, macitentan), PDE5 inhibitors (sildenafil, tadalafil), a soluble guanylate cyclase stimulator (riociguat), and prostacyclin analogs (treprostinil, iloprost, selexipag) were approved one after another, and in 2024–2025 the activin signaling inhibitor sotatercept was added, greatly expanding the possibilities of combination therapy.

2. Causes

Pathophysiologically, pulmonary arterial hypertension is the combined result of proliferation of pulmonary artery endothelial cells and smooth muscle cells, vascular remodeling, vasoconstriction, and intravascular thrombosis. Idiopathic PAH (IPAH) is sporadic with unknown cause, and heritable PAH (HPAH) is when there is a family history or a specific gene variant has been identified. ICD-10 I27.0 corresponds to the "primary" category covering these two subtypes.

The main molecular cause is abnormality of the TGF-β superfamily signaling pathway. BMPR2 (BMP receptor type 2), the receptor for BMP (bone morphogenetic protein) ligands, is involved in inhibiting proliferation and promoting apoptosis of endothelial cells and pulmonary artery smooth muscle cells. Loss of BMPR2 function eliminates this inhibitory function, causing abnormal proliferation of pulmonary artery cells and vascular remodeling. BMPR2 variants are found in about 75% of heritable PAH families and about 10–20% of sporadic IPAH.

Other mechanisms related to the etiology include ① reduced nitric oxide (NO) production in endothelial cells (eNOS dysfunction) → increased vasoconstriction, ② prostacyclin/thromboxane imbalance → increased platelet aggregation and vasoconstriction, ③ excess endothelin-1 production → promotion of vasoconstriction and smooth muscle proliferation, ④ serotonin (5-HT) overactivity → vasoconstriction and cell proliferation, and ⑤ oxidative stress and inflammation (T-cell and macrophage infiltration, CXCL12/CXCR4 axis). These mechanisms are the basis for current PAH treatment targets.

3. Genetics

The main causative gene of heritable PAH (HPAH) is BMPR2 (2q33.1), with an autosomal dominant inheritance pattern. Penetrance is incomplete: PAH develops during the lifetime of about 42% of women and about 14% of men carrying a BMPR2 variant, suggesting that sex hormones (estrogen) are cofactors modulating the phenotypic expression of BMPR2 deficiency. BMPR2 variants are of diverse types, including deletions, missense, nonsense, and splicing variants.

Causative genes other than BMPR2 include ACVRL1 (ALK1, hereditary hemorrhagic telangiectasia-PAH complex), ENG (endoglin), SMAD9 (SMAD8), CAV1 (caveolin-1), KCNK3 (TASK1 potassium channel), ATP13A3 (P5B-type ATPase), SOX17 (transcription factor), and GDF2 (BMP9 ligand). These also encode proteins involved in the BMP/TGF-β signaling pathway or endothelial cell function. Recently, additional risk variants such as SOX17 and HLA have been identified through genome-wide association studies (GWAS).

Clinically, genetic testing of PAH patients is recommended when heritable PAH has been diagnosed, in IPAH patients with a family history, and in patients with PAH onset at a young age. BMPR2 variant carriers tend to develop the disease at a younger age than noncarriers, show more severe hemodynamic abnormalities, have lower vasodilator response rates, and have a poorer prognosis. Therefore, confirmation of a BMPR2 variant influences prognostic prediction and the choice of treatment strategy.

4. General epidemiology

The prevalence of PAH (WHO Group 1) is reported at about 15–60 per million, depending on registry studies. The annual incidence is about 2–7 per million. IPAH is 2–3 times more common in women than in men (F:M≈2–3:1), and the mean age at diagnosis is 35–50 years. Compared with the past, diagnoses in older adults (>65 years) are increasing, which is attributed to reduced early mortality and improved diagnostic awareness.

Patients with heritable PAH carrying BMPR2 variants are diagnosed at a younger age (mean, early 30s) than those with IPAH and show more severe hemodynamic abnormalities. According to the French PAH Registry, 1-, 3-, and 5-year survival of PAH patients was about 87%, 67%, and 57%, respectively. In pediatric PAH, IPAH shows a more even sex ratio than in adults (F:M≈1:1), and severe PAH in children has a poorer prognosis.

In Korea, idiopathic and heritable pulmonary arterial hypertension are designated as rare diseases for Special Copayment Reduction (V202), and upon registration after confirmation by right heart catheterization (RHC), part of the treatment cost can be supported. Diagnostic delay remains a major problem, with a mean delay of 1–2 years reported from first symptom onset to diagnosis. This is because the early symptoms are nonspecific (exertional dyspnea, fatigue) and are mistaken for other conditions (asthma, anxiety disorders, etc.).

5. Pathophysiology

The core pathophysiology of PAH is elevated pulmonary vascular resistance (PVR) due to pulmonary arterial vascular remodeling. Vascular remodeling includes intimal proliferation, medial thickening, adventitial fibrosis, and formation of plexiform lesions, which narrow the pulmonary artery lumen and continuously increase resistance to blood flow.

Explained with a focus on the molecular mechanisms of BMPR2 loss of function: normally, upon BMP ligand binding, BMPR2 induces endothelial cell survival, inhibition of proliferation, and promotion of apoptosis via the SMAD1/5/8 pathway. In the state of haploinsufficiency due to BMPR2 variants, this balance is disrupted, endothelial cells and smooth muscle cells proliferate abnormally, and the TGF-β/ALK5 pathway becomes relatively dominant, promoting fibrosis and vasoconstriction. Endothelial dysfunction leads to reduced NO synthesis and reduced prostacyclin production, promoting vasoconstriction and platelet aggregation.

Overexpression of endothelin-1 (ET-1) causes potent vasoconstriction and smooth muscle cell proliferation via ETA/ETB receptors. This is the treatment target of endothelin receptor antagonists (ERAs). PDE5 inhibitors promote vasodilation through the NO-cGMP pathway, and sGC stimulators (riociguat) directly activate sGC to increase cGMP production. Prostacyclin analogs increase cAMP via the IP receptor, causing vasodilation and inhibition of platelet aggregation. These three pathways are the three main targets of current PAH drug therapy.

The right ventricle initially adapts to the overload with compensated hypertrophy, but with persistently increasing PVR it progresses to right ventricular fibrosis, right ventricular dilation, tricuspid regurgitation, and decline of right ventricular function (decompensated RV failure). Reduced cardiac output, hypotension, and reduced tissue perfusion ultimately lead to death.

6. Symptoms

The early symptoms of PAH are mostly nonspecific and are the main cause of diagnostic delay. The most common early symptom is exertional dyspnea, which at first appears only with strenuous exercise and gradually causes breathlessness even during daily activities. Symptom severity is classified by WHO functional class (FC) from FC I (asymptomatic) to FC IV (severe dyspnea at rest). At diagnosis, most patients are in FC II–III.

Fatigue and reduced exercise capacity are present and gradually worsen over time. Chest pain is presumed to be due to right ventricular ischemia and sometimes resembles left ventricular angina. Syncope often occurs during exercise and is due to insufficient cardiac output and an imbalanced vasodilatory response. Syncope is a poor prognostic factor for disease severity. Palpitations occur owing to reflex tachycardia or atrial arrhythmias resulting from reduced right ventricular function.

As right heart failure progresses, peripheral edema, abdominal distension (ascites), anorexia, nausea, and right upper quadrant discomfort (hepatic congestion) appear. Cough and hemoptysis occur in some patients and are related to peripheral pulmonary artery dilation or vascular rupture. Peripheral cyanosis appears when reduced cardiac output and arteriovenous shunting are severe. The combined manifestation of these symptoms causes a considerable decline in quality of life.

7. Signs (clinical findings)

Among auscultation findings in PAH, an accentuated pulmonic valve closure sound (P2) is the most specific and is sometimes heard at the apex or left sternal border. A pansystolic murmur due to tricuspid regurgitation may be heard at the lower left sternal border and increases with inspiration. Abnormal right ventricular S4 and S3 heart sounds may be heard. A right ventricular heave at the left sternal border due to right ventricular hypertrophy is palpable.

Elevated jugular venous pressure (JVP) is a sign of right heart failure, and abnormal pulsation of the internal jugular vein is observed. Hepatojugular reflux is positive, and hepatomegaly and abdominal tenderness appear. Pitting edema of the lower extremities starts around the ankles and progresses, and in severe cases scrotal or abdominal edema appears. At the end stage, ascites forms. Peripheral cyanosis and digital clubbing are observed when chronic hypoxemia is present.

On electrocardiography, right axis deviation, findings of right ventricular hypertrophy (RVH), and P pulmonale appear. On chest X-ray, dilation of the main pulmonary artery, dilation of the right descending pulmonary artery (>17 mm), and enlargement of the right ventricle and right atrium are observed. On echocardiography, right atrial·right ventricular dilation, increased tricuspid regurgitation velocity (>3.4 m/s), reduced right ventricular systolic function (decreased TAPSE, FAC), and D-shaped deformation of the left ventricle are characteristic. Elevated BNP/NT-proBNP reflects increased right ventricular wall stress and is used as a prognostic factor.

8. Screening

Screening of the general population is not recommended. Selective echocardiographic screening is recommended in specific high-risk groups. The possibility of pulmonary hypertension is selectively evaluated in ① carriers of BMPR2 or other HPAH-related gene variants, ② patients with systemic sclerosis (SSc) (annual echocardiography), ③ patients with mixed connective tissue disease, ④ patients with HIV infection (when symptoms occur), ⑤ those with congenital heart disease (systemic-to-pulmonary shunt), and ⑥ patients with cirrhosis or portal hypertension.

On echocardiographic screening, if the peak tricuspid regurgitation velocity (TRV) is 2.8 m/s or higher or there are indirect findings such as right ventricular dilation or septal displacement, the probability of pulmonary hypertension is high and further testing (right heart catheterization) is considered. The 2022 ESC/ERS pulmonary hypertension guidelines present the echocardiographic probability of PAH as "low/intermediate/high" based on the combination of TRV and other indirect findings. In families with heritable PAH, genetic testing for BMPR2 and others is performed to identify carriers before symptom onset, and periodic echocardiographic follow-up is recommended for them.

9. Diagnosis

PAH is confirmed by right heart catheterization (RHC). The diagnostic hemodynamic criteria are ① mean pulmonary artery pressure (mPAP) at rest ≥25 mmHg (2022 guideline revision: >20 mmHg), ② pulmonary artery wedge pressure (PAWP) or pulmonary venous pressure ≤15 mmHg, and ③ pulmonary vascular resistance (PVR) >3 Wood units. For a diagnosis of IPAH/HPAH, all other causes (left heart disease, lung disease, pulmonary embolism, systemic diseases, etc.) must be excluded.

The diagnostic process proceeds in steps. Step 1: assess the probability of pulmonary hypertension with history, physical examination, ECG, chest X-ray, and echocardiography. Step 2: exclude lung disease and chronic thromboembolic pulmonary hypertension (CTEPH) with pulmonary function tests (PFT), chest CT (HRCT), and ventilation-perfusion lung scan (V/Q scan). Step 3: blood tests (autoantibodies, HIV, liver function, BNP/NT-proBNP) and polysomnography (to exclude nocturnal hypoxemia). Step 4: confirm the diagnosis and obtain hemodynamic data by RHC. Step 5: during RHC, acute vasoreactivity testing to select candidates for calcium antagonists (using inhaled NO or intravenous epoprostenol). The positive criterion is a decrease in mPAP of ≥10 mmHg to mPAP≤40 mmHg with cardiac output maintained or increased.

Hemodynamic data obtained from RHC (mPAP, PVR, mRAP, CO, SvO2), BNP/NT-proBNP, WHO FC, 6-minute walk distance (6MWT), and echocardiographic indices of right ventricular function are integrated to classify risk as "low/intermediate/high" in four or three strata, which forms the basis for treatment strategy and prognostic prediction. Gene panel testing including BMPR2 is performed concurrently to determine whether HPAH is present.

10. Treatment

PAH treatment follows a risk-based strategy: treatment is decided after initial risk assessment and is intensified stepwise according to treatment response, with the aim of achieving the target of low risk. In IPAH patients with a positive pretreatment vasoreactivity test (less than about 10% of all), high-dose calcium channel blockers (CCB, amlodipine or diltiazem) can be used first.

Standard treatment for patients not eligible for calcium channel blockers (most patients) is as follows. In new low·intermediate-risk patients, oral two-drug initial combination therapy with an endothelin receptor antagonist (ERA, e.g., ambrisentan or macitentan) and a PDE5 inhibitor (e.g., tadalafil or sildenafil) is recommended. The AMBITION study (ambrisentan+tadalafil) and the SERAPHIN study (macitentan+PDE5i) support this strategy. In new high-risk patients, initial three-drug combination therapy adding intravenous epoprostenol or subcutaneous/intravenous treprostinil to the above two drugs is recommended.

The sGC stimulator riociguat cannot be combined with PDE5 inhibitors and is used as a strategy replacing PDE5i or in combination with an ERA. Sotatercept (an activin A/B signaling inhibitor, ActRIIA-Fc fusion protein) received FDA approval in 2024 and became a new option for three-drug combination added to the baseline ERA+PDE5i combination; in the STELLAR clinical trial it showed improvement in 6MWT and reduction of clinical worsening. The selective IP receptor agonist selexipag can also be used as combination therapy added to ERA+PDE5i. When treatment goals are not reached, stepwise escalation is performed, and when drug therapy ultimately fails, evaluation for lung transplantation is performed.

11. Prognosis

The median survival of untreated IPAH was reported as 2.8 years in the 1981 NIH registry study. With the introduction of modern PAH-specific drugs and combination treatment strategies, prognosis has improved greatly. In recent registry studies, 5-year survival is about 60–70%, which still reflects a poor prognosis. BMPR2 variant carriers tend to develop the disease at a younger age than noncarriers, show more severe hemodynamic abnormalities, have a lower rate of positive vasoreactivity, and have lower overall survival.

Poor prognostic factors include ① WHO FC III/IV, ② 6-minute walk distance <165 m, ③ markedly elevated BNP/NT-proBNP, ④ right ventricular dilation and dysfunction (echocardiographic TAPSE <15 mm, FAC <35%), ⑤ mRAP >8 mmHg, ⑥ cardiac index <2.0 L/min/m², ⑦ SvO2 <60%, ⑧ PVR >12 WU, and ⑨ carrying a BMPR2 variant. The goal of treatment response is reaching "low risk", and if low-risk criteria are not met at 3–6-month follow-up, aggressive treatment intensification is recommended. Pregnancy should be actively avoided in PAH patients because maternal mortality is very high (about 25–50%).

12. Prevention

Primary prevention of IPAH is currently impossible, but secondary prevention by avoiding known risk factors is partly possible. Avoid taking drugs associated with PAH, such as fenfluramine-class appetite suppressants, dasatinib, and repaglinide, or, when unavoidable, perform baseline echocardiography before use and monitor periodically. Patients with HIV infection suppress viral load with antiretroviral therapy (ART) and undergo regular echocardiography for early detection of pulmonary hypertension.

In carriers of BMPR2 or other heritable PAH-related gene variants, early diagnosis at the asymptomatic stage is attempted through periodic echocardiographic screening (at least every 1–3 years). Early diagnosis and starting initial combination therapy are the most important strategies for improving prognosis. To reduce diagnostic delay, education of health care providers and a system for rapid referral to specialized PAH centers are needed. In diagnosed patients, pregnancy must be strictly avoided because the risk of life-threatening complications is very high, and an effective contraceptive method is chosen (caution with estrogen-containing oral contraceptives due to thrombotic risk; progesterone-only methods or intrauterine devices preferred). Influenza and pneumococcal vaccination prevents worsening of pulmonary hypertension due to infection.

References

  1. Lane KB, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26(1):81-84. PMID: 10973254
  2. D'Alonzo GE, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349. PMID: 1863023
  3. Humbert M, et al. Pulmonary arterial hypertension. Nat Rev Dis Primers. 2019;5(1):51. PMID: 31337737
  4. Galiè N, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67-119. PMID: 26320113
  5. Frost AE, et al. The six-minute walk test (6MWT) as an endpoint in clinical trials of treatments for idiopathic PAH. Respir Med. 2005;99(9):1070-1078. PMID: 15962244
  6. Sitbon O, et al. Initial combination therapy with ambrisentan and tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834-844. PMID: 26308684
  7. Pulido T, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-818. PMID: 23984728
  8. Hoeper MM, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024. PMC: PMC11525349
  9. Humbert M, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388(15):1361-1370. PMID: 37010475
  10. Thenappan T, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. PMC: PMC6889979